<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0034-7523</journal-id>
<journal-title><![CDATA[Revista Cubana de Medicina]]></journal-title>
<abbrev-journal-title><![CDATA[Rev cubana med]]></abbrev-journal-title>
<issn>0034-7523</issn>
<publisher>
<publisher-name><![CDATA[Centro Nacional de Información de Ciencias MédicasEditorial Ciencias Médicas]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0034-75232019000400008</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Uso de nimotuzumab en paciente con astrocitoma anaplásico]]></article-title>
<article-title xml:lang="en"><![CDATA[Nimotuzumab in the treatment of a patient with anaplastic astrocytoma]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Elzaurdín Mora]]></surname>
<given-names><![CDATA[Rubén Alexander]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Lara Fernández]]></surname>
<given-names><![CDATA[Noralys]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Centro de Investigaciones Médico-Quirúrgica  ]]></institution>
<addr-line><![CDATA[La Habana ]]></addr-line>
<country>Cuba</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Universidad de Ciencias Médicas de La Habana Hospital General Docente Miguel Enríquez ]]></institution>
<addr-line><![CDATA[La Habana ]]></addr-line>
<country>Cuba</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>12</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>12</month>
<year>2019</year>
</pub-date>
<volume>58</volume>
<numero>4</numero>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_arttext&amp;pid=S0034-75232019000400008&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_abstract&amp;pid=S0034-75232019000400008&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_pdf&amp;pid=S0034-75232019000400008&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[RESUMEN  Introducción:  Nimotuzumab es una inmunoglobina de isotipo IgG1, obtenido por tecnología de ADN recombinante. La expectativa de vida de niños con tumores cerebrales recurrentes, refractarios a tratamientos a la cirugía, la radioterapia y la quimioterapia es de un mes aproximadamente. Con este tratamiento la supervivencia alcanza 44,5 meses.  Objetivos:  Presentar el caso clínico de un paciente con diagnóstico de Astrocitoma anaplásico que recibió tratamiento oncoespecífico concurrente con Nimotuzumab.  Presentación de caso:  Se realizó la descripción del diagnóstico, tratamiento y evolución de un paciente de 31 años de edad que fue diagnosticado con una neoplasia del sistema nervioso central. (Astrocitoma anaplásico). Recibió la combinación terapéutica de cirugía, radioterapia y anticuerpos monoclonales, lográndose una sobrevida de 39 meses.  Conclusiones: La adición del anticuerpo monoclonal al tratamiento estándar de los tumores cerebrales aumentó la sobrevida del paciente, convirtiéndose en una alternativa terapéutica segura, ventajosa y factible como parte del tratamiento convencional en las condiciones asistenciales.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[ABSTRACT  Introduction:  Nimotuzumab is an IgG1 isotype immunoglobin, obtained by recombinant DNA technology. Life expectancy is approximately one month in children with recurrent brain tumors, refractory to treatments to surgery, radiotherapy and chemotherapy. Survival reaches 44.5 months when using Nimotuzumab.  Objectives:  To report the clinical case of a patient diagnosed with anaplastic astrocytoma who received concurrent oncospecific treatment with Nimotuzumab.  Case report:  This paper describes the diagnosis, treatment and evolution of a 31-year-old male patient with neoplasm of the central nervous system (Anaplastic astrocytoma). He received the therapeutic combination of surgery, radiotherapy and monoclonal antibodies, achieving a survival of 39 months.  Conclusions:  The adding the monoclonal antibody to the standard treatment of brain tumors increased patient survival, making it a safe, advantageous and feasible therapeutic alternative as part of conventional treatment in healthcare conditions.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Sistema nervioso central]]></kwd>
<kwd lng="es"><![CDATA[gliomas de alto grado]]></kwd>
<kwd lng="es"><![CDATA[nimotuzumab]]></kwd>
<kwd lng="es"><![CDATA[anticuerpo monoclonal]]></kwd>
<kwd lng="en"><![CDATA[central nervous system]]></kwd>
<kwd lng="en"><![CDATA[high-grade gliomas]]></kwd>
<kwd lng="en"><![CDATA[nimotuzumab]]></kwd>
<kwd lng="en"><![CDATA[monoclonal antibody]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rodríguez]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Glioblastoma multiforme cerebral hemisférico Análisis de sobrevida de 65 casos tratados en el Departamento de Oncología del Hospital de Clínicas desde 1980 a 2000]]></article-title>
<source><![CDATA[Rev Méd Urug]]></source>
<year>2012</year>
<volume>28</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>250-61</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="">
<collab>Ministerio Salud pública</collab>
<source><![CDATA[Anuario Estadístico de Salud]]></source>
<year>2017</year>
</nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Molina]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Factores pronósticos en los tumores cerebrales]]></article-title>
<source><![CDATA[ANALES Sis San Navarra]]></source>
<year>2001</year>
<volume>24</volume>
<numero>^sSupl. 1</numero>
<issue>^sSupl. 1</issue>
<supplement>Supl. 1</supplement>
<page-range>63-72</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pérez Ortiz]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Astrocitoma anaplásico y glioblastoma multiforme Factores que influyen en la supervivencia]]></article-title>
<source><![CDATA[Revista Cubana Cirugía]]></source>
<year>2001</year>
<volume>40</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>87-91</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Castañeda]]></surname>
<given-names><![CDATA[CA]]></given-names>
</name>
<name>
<surname><![CDATA[Casavilca]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Orrego]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[García Corrochano]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Deza]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Heinike]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Glioblastoma análisis molecular y sus implicancias clínicas]]></article-title>
<source><![CDATA[Rev Peru Med Exp Salud Pública]]></source>
<year>2015</year>
<volume>32</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>316-25</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Suárez Martínez]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Nimotuzumab, inmunoterapia eficaz para el tratamiento de tumores epiteliales malignos]]></article-title>
<source><![CDATA[Biotecnología Aplicada]]></source>
<year>2014</year>
<volume>31</volume>
<page-range>150-8</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Alegría Loyola]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Tumores del sistema nervioso central]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Galnares Olalde]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Mercado]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<source><![CDATA[Revista Médica del Instituto Mexicano del Seguro Social]]></source>
<year>2017</year>
<volume>55</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>330-40</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chávez López]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Astrocitoma anaplásico multifocal sincrónico con presentación clínica de hemorragia lobar]]></article-title>
<source><![CDATA[Rev Mex Neurociencias]]></source>
<year>2016</year>
<volume>21</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>62-3</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Muñoz Carmona]]></surname>
<given-names><![CDATA[DM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Nuevas perspectivas en el tratamiento paliativo del glioblastoma multiforme y astrocitoma anaplásico recidivado con implantes de carmustina]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Faga Cantamessa]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[García Salazar]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Gómez Millán]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Bayo]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<source><![CDATA[Oncología (Barc.)]]></source>
<year>2005</year>
<volume>28</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>43-51</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pérez Ortiz]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Larga sobrevida en 5 pacientes con astrocitomas malignos]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Rodríguez Fuentes]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Figueredo Méndez]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Rodríguez Loureiro]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
<name>
<surname><![CDATA[Barroso García]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Armas Hernández]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<source><![CDATA[Rev Cubana Cir]]></source>
<year>2004</year>
<volume>43</volume>
<numero>1</numero>
<issue>1</issue>
</nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[López Aguilar]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Sobrevida de los pacientes con astrocitoma de alto grado que expresan el antígeno Ki67, atendidos en un hospital de pediatría]]></article-title>
<source><![CDATA[Gac Med Mex]]></source>
<year>2010</year>
<volume>146</volume>
<numero>2</numero>
<issue>2</issue>
</nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Arrieta]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
</person-group>
<source><![CDATA[Factores de crecimiento epidérmico en tumores cerebrales. Un blanco terapéutico. Mensaje bioquímico]]></source>
<year>2005</year>
<volume>29</volume>
</nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vega]]></surname>
<given-names><![CDATA[RAM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Tumores astrocíticos un acercamiento a una patología]]></article-title>
<source><![CDATA[Rev Méd Electrón]]></source>
<year>2012</year>
<volume>34</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>362-72</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tatter]]></surname>
<given-names><![CDATA[SB]]></given-names>
</name>
<name>
<surname><![CDATA[Wilson]]></surname>
<given-names><![CDATA[CB]]></given-names>
</name>
<name>
<surname><![CDATA[Harsh IV]]></surname>
<given-names><![CDATA[GR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Neuroepithelial tumors of the adult brain]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Youmans]]></surname>
<given-names><![CDATA[JR]]></given-names>
</name>
</person-group>
<source><![CDATA[Neurological surgery. A comprehensive reference guide to the diagnosis and management of neurosurgical problems]]></source>
<year>1996</year>
<volume>4</volume>
<page-range>2612-84</page-range><publisher-loc><![CDATA[Philadelphia ]]></publisher-loc>
<publisher-name><![CDATA[WB Saunders]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Solans]]></surname>
<given-names><![CDATA[JG]]></given-names>
</name>
<name>
<surname><![CDATA[Massó]]></surname>
<given-names><![CDATA[JFM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Quimioterapia de los tumores cerebrales]]></article-title>
<source><![CDATA[Neurología]]></source>
<year>1988</year>
<volume>3</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>19-25</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kornblith]]></surname>
<given-names><![CDATA[PL]]></given-names>
</name>
<name>
<surname><![CDATA[Walker]]></surname>
<given-names><![CDATA[MD]]></given-names>
</name>
<name>
<surname><![CDATA[Cassady]]></surname>
<given-names><![CDATA[JR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Tumores del sistema nervioso central]]></article-title>
<source><![CDATA[Rev Cubana Cir]]></source>
<year>2001</year>
<volume>40</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>87-91</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Brem]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Rozental]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Moskal]]></surname>
<given-names><![CDATA[JR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[What is the etiology of human brain tumor A report on the first Lebow conference]]></article-title>
<source><![CDATA[Cáncer]]></source>
<year>1995</year>
<volume>76</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>709-13</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Polednak]]></surname>
<given-names><![CDATA[AP]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Brain, others tumors of the central nervous system and eye cancer]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Flannery]]></surname>
<given-names><![CDATA[JT]]></given-names>
</name>
</person-group>
<source><![CDATA[Cancer]]></source>
<year>1995</year>
<volume>75</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>330-7</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Walker]]></surname>
<given-names><![CDATA[AE]]></given-names>
</name>
<name>
<surname><![CDATA[Robis]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Weinfeld]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Epidemiology of brain tumors The national survey of intracraneal neoplasms]]></article-title>
<source><![CDATA[Neurology]]></source>
<year>1985</year>
<volume>35</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>219-26</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Brem]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Thompson]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Long]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Patz]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Human brain tumors Differences in ability to stimulate angiogenesis]]></article-title>
<source><![CDATA[Surgical Forum]]></source>
<year>1980</year>
<volume>31</volume>
<page-range>471-3</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cohen]]></surname>
<given-names><![CDATA[EE]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Role of epidermal growth factor receptor pathway-targeted therapy in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck]]></article-title>
<source><![CDATA[J Clin Oncol]]></source>
<year>2006</year>
<volume>24</volume>
<numero>17</numero>
<issue>17</issue>
<page-range>2659-65</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Packer]]></surname>
<given-names><![CDATA[RJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Progress and challenges in childhood brain tumors]]></article-title>
<source><![CDATA[J Neurooncol]]></source>
<year>2005</year>
<volume>75</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>239-42</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sierra]]></surname>
<given-names><![CDATA[BEM]]></given-names>
</name>
<name>
<surname><![CDATA[León]]></surname>
<given-names><![CDATA[PMQ]]></given-names>
</name>
<name>
<surname><![CDATA[Laud]]></surname>
<given-names><![CDATA[RL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Gliomas malignos biología molecular y detalles oncogenéticos]]></article-title>
<source><![CDATA[Rev Méd Electrón]]></source>
<year>2018</year>
<volume>40</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>1100-11</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cardozo Oliver]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Estudio de una cohorte de pacientes adultos con tumores primarios de sistema nervioso central de la serie glial]]></article-title>
<source><![CDATA[Neurología Argentina,]]></source>
<year>2010</year>
<volume>2</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>240-6</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cáceres Lavernia]]></surname>
<given-names><![CDATA[HH]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Combinación de radioterapia y Nimotuzumab en paciente con metástasis cerebral]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Nenínger Vinageras]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[del Cristo Domínguez]]></surname>
<given-names><![CDATA[IS]]></given-names>
</name>
</person-group>
<source><![CDATA[Rev. electron. Zoilo]]></source>
<year>2015</year>
<volume>40</volume>
<numero>11</numero>
<issue>11</issue>
</nlm-citation>
</ref>
</ref-list>
</back>
</article>
